Market research
XBIT XBiotech Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 61M
- P/E ratio
- Not available
- Analyst target
- 18
- Dividend yield
- Not available
- Beta
- 0.8
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA98400H1029
- Market cap
- 61M
- P/E ratio
- Not available
- Analyst target
- 18
- Dividend yield
- Not available
- Beta
- 0.8
About
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Research context
XBiotech Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the XBIT discussion.
5 years, 6 months ago
XBiotech Inc is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.2.
XBiotech Inc's total revenue rose by inf% to $5M since the same quarter in the previous year.
Its net income has dropped by 100.3% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 30.5% to $-3M since the same quarter in the previous year.
Based on the above factors, XBiotech Inc gets an overall score of 3/5.